---
title: "Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295926197.md"
description: "Recently published data on the next-generation STAT3 inhibitor, TTI-109, revealed promising results in healthy volunteers. The study demonstrated the efficacy of the prodrug design, showing improved tolerability in participants. Additionally, significant reductions in disease-relevant immune cell populations were observed. These findings highlight the potential of TTI-109 as a treatment for various conditions. This represents a significant advancement in the field of drug development, with potential implications for a wide range of diseases."
datetime: "2026-08-14T11:01:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295926197.md)
  - [en](https://longbridge.com/en/news/295926197.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295926197.md)
---

# Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Recently published data on the next-generation STAT3 inhibitor, TTI-109, revealed promising results in healthy volunteers. The study demonstrated the efficacy of the prodrug design, showing improved tolerability in participants. Additionally, significant reductions in disease-relevant immune cell populations were observed. These findings highlight the potential of TTI-109 as a treatment for various conditions. This represents a significant advancement in the field of drug development, with potential implications for a wide range of diseases.

### Related Stocks

- [TVRD.US](https://longbridge.com/en/quote/TVRD.US.md)

## Related News & Research

- [Scott Galloway says GLP-1 drugs are a 'silver bullet' for America's woes, if we're not 'stupid enough' to get in the way](https://longbridge.com/en/news/295999435.md)
- [CMI adopts orphan drug field with dedicated center of excellence](https://longbridge.com/en/news/296242891.md)
- [Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing](https://longbridge.com/en/news/296318843.md)
- [Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands](https://longbridge.com/en/news/296027938.md)
- [Elicera corrects CARMA update, says 2 of 3 prior CAR T patients show tumor response, not all 3](https://longbridge.com/en/news/295928409.md)